A clinical prediction nomogram to assess risk of colorectal cancer among patients with type 2 diabetes

Lu-Huai Feng1,6, Tingting Su5,6, Kun-Peng Bu1, Shuang Ren3, Zhenhua Yang3, Cheng-En Deng2, Bi-Xun Li1* & Wei-Yuan Wei4*

Colorectal cancer remains a major health burden worldwide and is closely related to type 2 diabetes. This study aimed to develop and validate a colorectal cancer risk prediction model to identify high-risk individuals with type 2 diabetes. Records of 930 patients with type 2 diabetes were reviewed and data were collected from 1 November 2013 to 31 December 2019. Clinical and demographic parameters were analyzed using univariable and multivariable logistic regression analysis. The nomogram to assess the risk of colorectal cancer was constructed and validated by bootstrap resampling. Predictors in the prediction nomogram included age, sex, other blood-glucose-lowering drugs and thiazolidinediones. The nomogram demonstrated moderate discrimination in estimating the risk of colorectal cancer, with Hosmer–Lemeshow test \( P = 0.837 \), an unadjusted C-index of 0.713 (95% CI 0.670–0.757) and a bootstrap-corrected C index of 0.708. In addition, the decision curve analysis demonstrated that the nomogram would be clinically useful. We have developed a nomogram that can predict the risk of colorectal cancer in patients with type 2 diabetes. The nomogram showed favorable calibration and discrimination values, which may help clinicians in making recommendations about colorectal cancer screening for patients with type 2 diabetes.

Colorectal cancer is one of the most common and aggressive clinical gastrointestinal cancer that causes a serious threat to human life and health1, accounting for approximately seven hundred thousand annual deaths worldwide2. Despite the rapid development of diagnostic and treatment methods, the 5-year survival rate for colorectal cancer is \( \approx 50\% \) overall3, although this rate for colorectal cancer diagnosed in the early stages is \( > 90\% \)4. The reason for this abysmal prognosis is that the vast majority of colorectal cancer patients are diagnosed at an advanced stage5. Therefore, early diagnosis of colorectal cancer is particularly important. Unfortunately, huge resources have been invested in the prevention and early diagnosis of colorectal cancer, but there is a limitation on the effective and early diagnosis of colorectal cancer6.

Screening can reduce the incidence and mortality of colorectal cancer by 30% and 50%, respectively7. Current screening methods for colorectal cancer mainly include flexible sigmoidoscopy, colonoscopy, fecal occult blood testing, double-contrast barium enema, stool DNA testing, and computed tomographic colonography8. However, these examinations are invasive or time-consuming or expensive, and it is not feasible to screen the general population for colorectal cancer. To improve the early diagnosis of this disease, we need to broaden our understanding of it.

International screening guidelines recommend that screening for colorectal cancer starts at 50 years of age for the average risk group and 50–75 years of age as the target age group for colorectal cancer screening9,10. It is worth mentioning that diabetes is one of the indicators of the average risk group evaluation in China’s guidelines.

1Department of Comprehensive Internal Medicine, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 2Department of Urology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 3Department of Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. 4Department of Gastrointestinal Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. 5Department of ECG Diagnostics, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. 6These authors contributed equally: Lu-Huai Feng and Tingting Su. 406221047@qq.com
Many epidemiological studies have reported that type 2 diabetic patients are at a higher risk of developing colorectal cancer compared with non-diabetic patients\(^\text{11-13}\). A meta-analysis showed that the risk of developing colorectal cancer in type 2 diabetic patients is 20–40% greater than non-diabetic individuals\(^\text{14}\). Diabetes may influence the neoplastic process by several mechanisms, including hyperinsulinemia (either endogenous due to insulin resistance or exogenous due to administered insulin or insulin secretagogues), hyperglycemia, or chronic inflammation\(^\text{15}\). However, due to the high incidence of type 2 diabetes mellitus in the general population and the lack of a low-risk and low-cost colorectal cancer screening method, it is not feasible to conduct mass colorectal cancer screening in all patients with type 2 diabetes mellitus. Besides, targeted screening for colorectal cancer (e.g., using flexible sigmoidoscopy) may be feasible if diabetic individuals at the highest risk for colorectal cancer could be identified.

Based on existing knowledge, a variety of epidemiological and/or clinical characteristics (e.g., weight changes\(^\text{15}\), lifestyle factors such as smoking\(^\text{16}\), medications such as metformin, insulin\(^\text{17}\)) can be used to predict the risk of colorectal cancer in patients with type 2 diabetes mellitus. Similar risk prediction models exist for other diseases, such as diabetic nephropathy\(^\text{18}\) and pancreatic ductal adenocarcinoma-associated diabetes mellitus\(^\text{19}\). To date, epidemiological studies of colorectal cancer predictors associated with type 2 diabetes mellitus have been limited to the assessment of individual predictors. The nomogram has been accepted as a reliable tool to create a simple intuitive graph for a statistical predictive model that quantifies the risk of a clinical event\(^\text{20,21}\). This study aimed to identify a combination of variables that would enable a highly accurate prediction of colorectal cancer in patients with type 2 diabetes. In addition, a nomogram for predicting the risk of colorectal cancer was constructed for patients with type 2 diabetes to effectively identify patients at high risk for colorectal cancer.

**Material and methods**

This retrospective study was performed with approval from the Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University ( Approval N. LW2020010). The data are anonymous, and the requirement for informed consent was therefore waived. This study was conducted per the Helsinki Declaration.

**Patients.** This was a retrospective study. Electronic records were used to identify patients diagnosed colorectal cancer with type 2 diabetes between November 1, 2013, and September 31, 2019, at the Affiliated Tumor Hospital of Guangxi Medical University. Patients with a clear diagnosis of type 2 diabetes before the diagnosis of colorectal cancer were included in the study, while those with two or more types of cancers were excluded.

**Data collection.** Participants were divided into colorectal cancer group (n = 118) and non-colorectal cancer group (n = 812). Clinical parameters and demographic data were collected at the time of colorectal cancer diagnosis, including age, sex, duration of diabetes (months), use of blood glucose-lowering drugs, history of smoking, body mass index (BMI), and family history of colorectal cancer. The duration of diabetes was defined as the period from first diagnosis of type 2 diabetes to the diagnosis of malignancy. The diagnosis of type 2 diabetes in our institution complied with World Health Organization criteria\(^\text{22}\). Blood glucose-lowering drugs included insulin, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas and other blood-glucose-lowering drugs known as Chinese medicine or proprietary Chinese medicine of blood glucose-lowering drugs (Note: no patients in our study cohort used DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors). Family history of colorectal cancer was defined as more than one first-degree relative with colorectal carcinoma. Smoking was defined as the number of packs of cigarettes (1 pack = 20 cigarettes) smoked daily per year, including current smokers and ex-smokers\(^\text{23}\).

**Statistical analysis.** The statistical analyses were performed in SPSS version 26.0 (IBM Corp, Armonk, NY, USA), and graphics produced with R software (rms\(^\text{24}\) in R version 3.6.2; https://www.r-project.org/). For all analyses, statistical significance was set at \(P < 0.05\). Continuous variables are presented as median and range (M (P25, P75)) or mean ± standard deviation. Categorical variables are presented as whole numbers and proportions. Differences between the groups were assessed using the chi-square test, \(t\)-test, or Wilcoxon rank-sum test. The assumption of linearity in the logit for the continuous variable was assessed and the significance of each variable in the cohort was assessed using univariate logistic regression to determine the independent predictor for colorectal cancer. All variables with \(P < 0.05\) in the univariate logistic analyses were further assessed by multivariable logistic regression using backward stepwise selection. A clinical prediction nomogram to assess risk of colorectal cancer was constructed based on the results from the final multivariable logistic regression using the R software. Multicollinearity was checked before determining the final model.

Calibration curves were plotted to calibrate the nomogram. The C-index was used to evaluate discriminative ability, ranging from 0.5 (absence of discrimination) to 1 (perfect discrimination)\(^\text{25}\). In addition, the nomogram was subjected to 1000 bootstrap resamples for internal validation to assess predictive accuracy\(^\text{26}\).

Decision curve analysis was conducted by using the R software (rms\(^\text{27}\) in R version 3.6.2) to determine the clinical utility of the nomogram by quantifying the net benefit at different threshold probabilities. The net benefit was calculated by subtracting the proportion of false positives from the proportion of true positives, and weighting by the relative harm of foregoing treatment compared with the negative consequences of an unnecessary treatment\(^\text{28}\).

**Results**

A total of 930 patients were enrolled to develop and validate our predictive nomogram model. The clinical characteristics of patients are summarized in Table 1. Of the 930 patients, 544 (58.5%) were males and 386 (41.5%) were females, with the age of patients ranging from 33 to 86 years old (median: 60 years). The colorectal cancer
group comprised of 118 (12.7%) patients. Overall, compared with the No-Colorectal cancer group, older patients, patients with longer duration of diabetes, male patients, and patients using thiazolidinediones are more likely to develop colorectal cancer.

**Selected predictors for model.** After univariate logistic analysis (Table 2), variables including age, duration of diabetes, sex, BMI, thiazolidinediones and other blood-glucose-lowering drugs were included in the multivariable logistic regression analysis. The multivariable logistic analysis based on the backward stepwise approach demonstrated that the occurrence of colorectal cancer was significantly related to age (P < 0.001), sex (P < 0.001), other blood-glucose-lowering drugs (P = 0.024), and thiazolidinediones (P < 0.001) (Table 3). Overall, compared with the No-Colorectal cancer group, T2DM patients in the following categories (male, with longer duration of diabetes, older, using thiazolidinediones and other blood-glucose-lowering drugs) are at higher risk of colorectal cancer. In particular, there were no statistical differences in insulin and metformin in this study.

**Table 1.** Clinical characteristics of patients. Other blood-glucose-lowering drugs: defined as Chinese medicine or proprietary Chinese medicine of blood-glucose-lowering drugs. No patients in our study cohort used DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. BMI body mass index.

| Variable                                      | Colorectal cancer group (n = 118) | No-Colorectal cancer group (n = 812) | P value |
|-----------------------------------------------|----------------------------------|--------------------------------------|---------|
| Age, years                                    | 63 (56.69)                       | 59 (53.65)                           | <0.001  |
| Duration of diabetes, month                   | 46 (12.84)                       | 24 (6.68)                            | <0.001  |
| Sex, N (%)                                    |                                  |                                      |         |
| Male                                          | 98 (83.1)                        | 446 (54.9)                           | <0.001  |
| Female                                        | 20 (16.9)                        | 366 (45.1)                           |         |
| BMI, kg/m²                                     | 23.0 (21.6, 25.1)                | 23.5 (21.5, 25.9)                    | 0.139   |
| Smoking, yes, N (%)                           | 45 (38.1)                        | 273 (33.6)                           | 0.334   |
| Family history of colorectal cancer, yes, N (%)| 89 (13.6%)                       | 54 (12.4%)                           | 0.615   |

**Table 2.** Univariate logistic regression analysis of the predictor of Colorectal Cancer. Other blood-glucose-lowering drugs: defined as Chinese medicine or proprietary Chinese medicine of blood-glucose-lowering drugs. No patients in our study cohort used DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors. BMI body mass index.

| Variable                                      | β        | Odds ratio (95% CI)        | P value |
|-----------------------------------------------|----------|---------------------------|---------|
| Age, years                                    | 0.043    | 1.044 (1.023–1.066)       | <0.001  |
| Duration of diabetes, month                   | 0.003    | 1.003 (1.000–1.005)       | 0.041   |
| Family history of colorectal cancer           | 0.132    | 1.141 (1.722–1.805)       | 0.572   |
| Sex                                           | −1.392   | 0.249 (0.151–0.410)       | <0.001  |
| BMI, kg/m²                                     | −0.082   | 0.922 (0.914–0.929)       | <0.001  |
| Smoking, yes, N (%)                           | 0.196    | 1.217 (0.817–1.814)       | 0.335   |

**Blood-glucose-lowering drugs**

| Variable                                      | β        | Odds ratio (95% CI)        | P value |
|-----------------------------------------------|----------|---------------------------|---------|
| Insulin, yes, N (%)                           | 0.371    | 1.449 (0.908–2.311)       | 0.119   |
| Thiazolidinediones, yes, N (%)                | 1.728    | 5.627 (2.055–15.409)      | 0.001   |
| Alpha glucosidase inhibitors, yes, N (%)     | 0.367    | 1.444 (0.835–2.497)       | 0.188   |
| Sulfonylureas, yes, N (%)                     | −0.503   | 0.605 (0.315–1.159)       | 0.130   |
| Metformin, yes, N (%)                         | 0.418    | 1.519 (0.957–2.412)       | 0.076   |
| Other blood-glucose-lowering drugs            | 0.545    | 1.724 (1.044–2.846)       | 0.033   |
| Combination of oral drugs and insulin, yes, N % | 0.405    | 1.500 (0.608–3.703)       | 0.379   |
| Combination oral drugs, yes                   | 0.518    | 1.679 (0.989–2.851)       | 0.055   |
Predictive nomogram for the risk of colorectal cancer.

Based on the final multivariate logistic regression, a nomogram was established that included 4 significant predictors for colorectal cancer prediction (Fig. 1). A total score was generated using age, sex, other blood-glucose-lowering drugs, and thiazolidinediones. Briefly, the nomogram finds the position of each variable on the corresponding axis, draws a line to the points axis for the number of points, adds the points from all of the variables, and draws a line from the total points axis to determine the colorectal cancer probabilities at the lower line of the nomogram.

Performance of the nomogram. To validate the performance of the resulting nomogram, we performed internal validation by using the bootstrap method with 1000 repetitions. The nomogram demonstrated moderate discrimination in estimating the risk of colorectal cancer, with Hosmer–Lemeshow test P = 0.837, an unadjusted C index of 0.713 (95% CI 0.670–0.757), and a bootstrap-corrected C index of 0.708, indicating favorable discrimination. In addition, overall calibration plots were outstanding for the occurrence of colorectal cancer between the probabilities predicted by the nomogram and actual probabilities (Fig. 2).

Table 3. Multivariate logistic multivariable regression analysis of the predictor of colorectal cancer. Other blood-glucose-lowering drugs defined as Chinese medicine or proprietary Chinese medicine of blood-glucose-lowering drugs. BMI body mass index.

| Variable                              | $\beta$  | Odds ratio (95% CI)          | P value |
|---------------------------------------|----------|-----------------------------|---------|
| Sex                                   | −1.416   | 0.243 (0.144–0.408)         | < 0.001 |
| Duration of diabetes                  | 0.001    | 1.001 (0.998–1.004)         | 0.397   |
| Age                                   | 0.044    | 1.045 (1.022–1.068)         | < 0.001 |
| BMI                                   | −0.028   | 0.972 (0.910–1.039)         | 0.403   |
| Thiazolidinediones                    | 2.131    | 8.426 (2.784–25.508)        | < 0.001 |
| Other blood-glucose-lowering drugs    | 0.605    | 1.831 (1.083–3.098)         | 0.024   |

Figure 1. Nomogram developed with sex, age, other blood-glucose-lowering drugs, and thiazolidinediones incorporated.
Clinical use of nomogram. The decision curve analysis (DCA) for the prediction nomogram and that for the model with single predictor is presented in Fig. 3. The final DCA showed that if the threshold probability of patients or clinicians is between 10 and 45%, screening strategies based on our nomogram colorectal cancer risk estimates resulted in superior net benefit than screen-none or screen-all strategies. Within this range, the predictive effect of nomogram is better than that of a single predictor, respectively.

Discussion

We developed and internally validated a simple intuitive statistical predictive model to quantify colorectal cancer-associated diabetes mellitus among patients with type 2 diabetes mellitus. The model was developed in a diabetes type 2 cohort and focused on demographic and clinical variables that would be routinely available at the time of diabetes diagnosis. In estimating the risk of colorectal cancer, the final model showed good discrimination and calibration; with the C-index was 0.713 (0.734 via bootstrapping validation) and the Hosmer–Lemeshow test showed no significant statistic (P = 0.837).

In recent years, colorectal cancer has increased in incidence and a tendency to start at a younger age29, accounting for nearly seven hundred thousand deaths worldwide annually2. Radical surgical excision of early-stage colorectal cancer results in a high 5-year survival rate of up to 90%, but in metastatic colorectal cancer, this rate decreases to 15%4. Early diagnosis and treatment play an important role in reducing mortality and morbidity in colorectal cancers. Although colorectal cancer morbidity and mortality are high, universal screening using biomarkers, such as a carcinoembryonic antigen or clinical tests (eg., flexible sigmoidoscopy, colonoscopy, fecal occult blood testing or computed tomographic colonography) is not feasible. While highly specific and sensitive, the modalities of clinical diagnosis entail substantial risk and/or cost. Therefore, novel prediction models and screening methods for detecting asymptomatic early-stage disease are urgently needed, which would be both efficient and cost-effective30.

Epidemiological studies suggest DM is associated with an increased risk of colorectal cancer, especially T2DM31. A meta-analysis showed that the risk of developing colorectal cancer in type 2 diabetic patients is 20–40% greater than non-diabetic individuals14. However, conducting mass colorectal cancer screening using costly and/or invasive tests among all patients with type 2 diabetes mellitus would not be an effective approach because the vast majority of these patients do not have colorectal cancer-associated diabetes mellitus. Over-screening may lead to overtreatment and cause more harm than gain. In recent decades, the rapidly increasing incidence and relatively stable mortality of thyroid and prostate cancer in many countries, including China, the USA, and the UK could be partly due to overdiagnosis with ultrasonic or prostate-specific antigen screening tests32. By identifying high-risk patients for biomarker evaluation or conclusive diagnostic testing, our predictive model provides a low-risk and low-cost solution to this problem.

As far as we know, epidemiologic studies of colorectal cancer-associated type 2 diabetes mellitus have been limited to assessing individual predictors including age29, sex33, lifestyle factors34 (e.g. obesity, unfavorable diets, and low levels of physical activity) and blood-glucose-lowering drugs35. However, most findings from conducted studies may be possibly methodologically biased making it difficult to make an accurate prediction based on individual risk factors. Our findings indicate individualized patterns of demographic and clinical risk that can help identify patients with T2DM who may benefit from referral to services and over screening for colorectal cancer.

The most important and final contention for using the nomogram is the character need for further fitting or care. However, although the nomogram shows an overall excellent risk prediction performance, it still cannot
accurately capture the clinical outcome of a certain level of discrimination or miscalibration. Therefore, the decision curve analysis was performed to determine whether the nomogram judgment could be beneficial to explain the clinical utility. This method offers novel insight into clinical outcomes based on the threshold probability from which the net benefit can be derived. The decision curve showed that applying the nomogram in our study to predict colorectal cancer provides more advantages than either the screen-all-patients or the screen-none scheme if the threshold prediction of a patient or doctor is 10–45%.

There are certain limitations to the nomogram presented herein. First of all, we constructed the prediction nomogram based on the retrospective review of medical records, the database did not include other risk factors for colorectal cancer such as dietary patterns and lifestyle changes such as exercising and consumption of processed meat. Thus, restricted in using certain factors such as regions and races may have limited the power of our nomogram to identify their significance. However, we can continuously adjust the parameters in actual application, making the nomogram better suited for practical application. Second, our nomogram should be viewed as a case-screening approach to identify patients with T2DM who should receive additional definitive diagnostic testing but not as a diagnostic test. Third, given colorectal carcinoma normally develops from polyps taking 10–15 years, patients may already be living with pre-cancerous lesions at the time of T2DM diagnosis. However, because colonoscopy is an invasive examination, it is difficult to perform universally. Indeed, the final result is a simple and interpretable model for colorectal cancer prediction based on demographic and clinical variable, which can be easily applied in the screening of patients with T2DM, with economical and low-risk. The forecasting model can be optimized based on additional databases including the severity of diabetes and wider geographic recruitment so as to achieve better prediction accuracy for future use.

**Conclusion**

We have developed a nomogram that can predict the risk of colorectal cancer in patients with T2DM. The nomogram showed favorable calibration and discrimination values, which may help clinicians in making recommendations about colorectal cancer screening for patients with T2DM.
References

1. Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 64(1), 9–29 (2014).
2. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
3. Jemal, A. et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43–66 (2007).
4. Jones, P., Cade, J. E., Evans, C. E., Hancock, N. & Greenwood, D. C. Does adherence to the World Cancer Research Fund/American Institute of Cancer Research Cancer prevention guidelines reduce risk of colorectal cancer in the UK Women's Cohort Study? Br. J. Nutr. 119(3), 340–348 (2018).
5. Sharma, R., Manson, M., Gescher, A. & Steward, W. Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur. J. Cancer 37(1), 12–22 (2001).
6. Beitia, M. et al. Altered expression of renin-angiotensin system receptors throughout colorectal adenoma-adenocarcinoma sequence. Int. J. Med. Sci. 16(6), 813 (2019).
7. Atkin, W. S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726), 1624–1633 (2010).
8. Levin, B. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J. Clin. 58(3), 130–160 (2008).
9. Benson, A. B. et al. NCCN guidelines insights: colon cancer, version 2.2018. J. Natl. Compr. Cancer Netw. JNCCN 16(4), 359–369 (2018).
10. Digestive Endoscopy Professional Committee of Chinese Medical Doctor Association Endoscope Branch. Chinese consensus of early colorectal cancer screening (2019, Shanghai). Chin. J. Dig. 39(10), 664–668 (2019).
11. Campbell, P. T. et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 139(4), 1138–1146 (2010).
12. Stein, K. B. et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig. Dis. Sci. 55(7), 1839–1851 (2010).
13. Giovannucci, E. et al. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60(4), 207–221 (2010).
14. Larsson, S. C., Orsini, N. & Wolk, A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst. 97(22), 1679–1687 (2005).
15. Vrieling, A. & Kampman, E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am. J. Clin. Nutr. 92(3), 471–490 (2010).
16. Botteri, E. et al. Smoking and colorectal cancer: a meta-analysis. JAMA 300(23), 2765–2778 (2008).
17. Komninos, D., Aymon, A., Richie, J. P. Jr. & Rigas, B. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. 228(4), 396–405 (2003).
18. Yang, Z., Peng, L., Huang, Y. & Xia, N. A differential diagnosis model for diabetic nephropathy and non-diabetic renal disease in patients with type 2 diabetes complicated with chronic kidney disease. Diabetes Metab. Syndr. Obes. 12, 1963 (2019).
19. Boursi, B. et al. A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes. Gastroenterology 152(4), 840–850.e843 (2017).
20. Huang, Y. et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J. Clin. Oncol. 34(18), 2157–2164 (2016).
21. Iasonos, A., Schrag, D., Raj, G. V. & Panagreas, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26(8), 1364–1370 (2008).
22. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group [Meeting Held in Geneva from 11 to 16 February 1985] [WHO, Geneva, 1985].
23. Taghizadeh, N., Vonk, J. M. & Boezen, H. M. Lifetime smoking history and cause-specific mortality in a cohort study with 43 years of follow-up. PloS one 11(4), e0153310 (2016).
24. Ir FEH. rns: Regression Modeling Strategies. R package version 6.0-0. https://CRAN.R-project.org/package=rms (2020). Accessed 06 March 2020.
25. Harrell, F. E., Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. JAMA 247(18), 2543–2546 (1982).
26. Harrell, F. E. Jr., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing model, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15(4), 361–386 (1996).
27. Brown M. rmda: Risk Model Decision Analysis. R package version 1.6. https://CRAN.R-project.org/package=rmda (2018).
28. Vickers, A. J., Cronin, A. M., Elkin, E. B. & Gonen, M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform. Decis. Mak. 8(1), 53 (2008).
29. Goldberg, H. et al. Coalitions in young patients: is it a distinct clinical entity? Int. J. Clin. Oncol. 21(4), 684–695 (2016).
30. Kenner, B. J., Chari, S. T., Cleeter, D. F. & Go, V. L. W. Early detection of sporadic pancreatic cancer: strategic map for innovation—a white paper. Pancreas 44(5), 686 (2015).
31. Suh, S. & Kim, K. W. Diabetes and cancer: is diabetes causally related to cancer?. Diabetes Metab. J. 35(3), 193–198 (2011).
32. Feng, R. M., Zong, Y. N., Cao, S.-M. & Xu, R.-H. Current cancer situation in China: good or bad news from the 2018 global cancer statistics?. Cancer Commun. (Lond.) 39(1), 22 (2019).
33. De Kort, S. et al. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci. Rep. 7, 46527 (2017).
34. Park, S.-Y., Wilkins, L. R., Haiman, C. A. & Le Marchand, L. Physical activity and colorectal cancer risk by sex, race/ethnicity, and subsite: the multiethnic cohort study. Cancer Prev. Res. (Phila.) 12(5), 315–326 (2019).
35. Currie, C. J., Poole, C. D. & Gale, E. A. M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9), 1766–1777 (2009).
36. Van Calster, B. & Vickers, A. J. Calibration of risk prediction models: impact on decision-analytic performance. Med. Decis. Mak. 35(2), 162–169 (2015).
37. Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br. J. Surg. 102(3), 148–158 (2015).

Acknowledgements

This work was supported by a grant from the Guangxi Clinical Research Center for Colorectal Cancer, Natural Science Foundation of Guangxi (No. 2018GXNSFBA138016) and self-financing project of Traditional Chinese Medicine Administration of Guangxi Zhuang Autonomous Region (No. GZZC2020234).
Author contributions
L.-H.F. participated in study concept, design, and drafting of the manuscript; T.S. participated in the statistical analysis and manuscript revision; K.-P.B., S.R., Z.Y., and C.-E.D. participated in acquisition, analysis and interpretation of data; W.W., B.-X.L. participated in critical revision of the manuscript for important intellectual content.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to B.-X.L. or W.-Y.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020